Banque Cantonale Vaudoise’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$389K Sell
2,256
-62
-3% -$11.5K 0.01% 533
2025
Q4
$462K Buy
2,318
+26
+1% +$4.72K 0.02% 462
2025
Q3
$359K Sell
2,292
-197
-8% -$31.3K 0.01% 487
2025
Q2
$378K Sell
2,489
-73
-3% -$9.73K 0.02% 472
2025
Q1
$386K Buy
+2,562
New +$430K 0.02% 482
2024
Q3
$425K Sell
2,159
-73
-3% -$15.2K 0.02% 406
2024
Q2
$461K Buy
2,232
+215
+11% +$48.7K 0.02% 447
2024
Q1
$547K Buy
2,017
+126
+7% +$30.1K 0.02% 415
2023
Q4
$447K Sell
1,891
-820
-30% -$161K 0.02% 463
2023
Q3
$532K Sell
2,711
-44
-2% -$9.03K 0.03% 471
2023
Q2
$579K Buy
2,755
+191
+7% +$38K 0.03% 460
2023
Q1
$517K Sell
2,564
-27
-1% -$6.12K 0.03% 442
2022
Q4
$565K Buy
2,591
+36
+1% +$7.86K 0.03% 421
2022
Q3
$502K Sell
2,555
-31
-1% -$6.69K 0.03% 480
2022
Q2
$553K Sell
2,586
-41
-2% -$10K 0.03% 466
2022
Q1
$746K Sell
2,627
-2,263
-46% -$698K 0.03% 458
2021
Q4
$1.84M Sell
4,890
-380
-7% -$148K 0.07% 259
2021
Q3
$2.17M Buy
5,270
+244
+5% +$101K 0.09% 212
2021
Q2
$1.86M Buy
5,026
+2,268
+82% +$757K 0.08% 248
2021
Q1
$799K Sell
2,758
-566
-17% -$157K 0.04% 425
2020
Q4
$831K Buy
3,324
+433
+15% +$103K 0.05% 351
2020
Q3
$655K Buy
2,891
+35
+1% +$7.26K 0.04% 369
2020
Q2
$498K Buy
2,856
+275
+11% +$43.9K 0.04% 387
2020
Q1
$326K Sell
2,581
-250
-9% -$37.5K 0.03% 485
2019
Q4
$432K Buy
+2,831
New +$392K 0.03% 516

Other funds holding CRL

Banque Cantonale Vaudoise's CRL Position: Q1 2026 in Review

Banque Cantonale Vaudoise reduced its Charles River Laboratories (CRL) stake by 2.7% in Q1 2026, selling an estimated $11.5K and leaving 2,256 shares worth $389K. The position accounts for 0.01% of the portfolio, ranked #533.

Banque Cantonale Vaudoise first reported a position in CRL in Q4 2019 and has held it in 25 quarters since. The position peaked at $2.17M in Q3 2021. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Banque Cantonale Vaudoise held 2,256 shares of Charles River Laboratories worth $389K as of Q1 2026.
  • Banque Cantonale Vaudoise sold 62 Charles River Laboratories shares in Q1 2026, an estimated $11.5K.
  • Charles River Laboratories made up 0.01% of Banque Cantonale Vaudoise's portfolio in Q1 2026, its #533 holding.
  • Banque Cantonale Vaudoise first reported a position in Charles River Laboratories in Q4 2019 and has held it in 25 quarters since.
  • Banque Cantonale Vaudoise's Charles River Laboratories position peaked at $2.17M in Q3 2021.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Banque Cantonale Vaudoise's 13F filing for Q1 2026, filed 20 Apr 2026.